Mereo BioPharma Group plc (MREO) Stock Forecast
MREO analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.00 / 5 from 8 analysts
- Price target
- $1.98 average of analyst targets
- Upside to target
- +554.1% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.01
- 52-week range
- $0.24 – $2.31
MREO analyst ratings
8 analystsNumber of analysts at each rating.
MREO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MREO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.03 | −$0.01 | −$0.01 | −44.7% | 6 |
| Current fiscal year (2026) | −$0.04 | −$0.12 | −$0.02 | −$0.04 | −11.1% | 6 |
| Next fiscal year (2027) | −$0.02 | −$0.05 | $0.02 | −$0.04 | +58.4% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MREO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 5 |
| Next fiscal year (2027) | $14.4M | $0 | $56.9M | 0.0% | 6 |
MREO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MREO revenue: reported and forecast
MREO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | +57.1% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.03 | −$0.03 | −$0.04 | −$0.04 | −$0.04 | +47.9% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.03 | −$0.03 | −$0.02 | −$0.02 | −$0.02 | −38.9% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MREO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MREO beat in 7 of 12.
What analysts expect from MREO
8 analysts cover Mereo BioPharma; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.98, 554.1% above the latest close of $0.30. Analysts expect earnings of −$0.04 per share for 2026, −11.1% from a year earlier. For 2027 the average estimate is −$0.02 per share on revenue of $14.4 million. Mereo BioPharma beat the EPS estimate in 7 of the last 12 quarters.
Related: MREO income statement, MREO key metrics, MREO chart. See the MREO stock overview for the latest quote and news.
MREO forecast FAQ
What is Mereo BioPharma's price target?
The average analyst price target for Mereo BioPharma is $1.98, 554.1% above the latest close of $0.30.
Is Mereo BioPharma a buy, hold or sell?
Of 8 analysts covering Mereo BioPharma, 4 rate it a strong buy, 1 a buy, 2 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Mereo BioPharma's EPS forecast?
Analysts forecast −$0.04 per share for 2026 (range −$0.12 to −$0.02); for 2027 the estimate is −$0.02.
When does Mereo BioPharma report earnings?
Mereo BioPharma is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.01.
Does Mereo BioPharma usually beat earnings estimates?
Mereo BioPharma reported EPS at or above the analyst estimate in 7 of the last 12 quarters.